Superworth

Celldex Therapeutics price to book ratio CLDX

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
3.2×
10-year median
2.6×
Against its 10-year history
60th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 14.2×
Peer median
8.4×

Celldex Therapeutics' price to book ratio is 3.2× as of Oct 23, 2026.

That is above its ten-year median of 2.6×, close to the middle of its last ten years.

Over that time it ranged from 0.2× in Mar 2020 to 14.2× in Oct 2021.

The median for 9 diagnostics and research stocks of a similar size is 8.4×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.2×2.6×6.7×
20252.9×1.4×3.3×
20242.1×2.0×8.1×
20237.6×3.9×7.6×
20226.1×2.5×6.1×
20214.1×3.0×14.2×
20203.0×0.2×3.9×
20190.4×0.3×0.8×
20180.3×0.3×1.9×
20171.8×1.1×1.9×
20161.7×1.1×3.9×
20154.9×3.4×12.9×
20146.8×3.9×16.3×
201312.1×4.8×16.5×
20124.5×1.7×4.6×
20111.4×1.1×1.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Celldex Therapeutics' size, closest first, today.

CompanyPrice to book ratio
CLDXCelldex Therapeutics3.2×
CDNACareDx8.4×
VCYTVeracyte2.8×
BLLNBillionToOne9.5×
LNTHLantheus5.0×
CAICaris Life Sciences15.3×
BIOBio-Rad Laboratories1.4×
NRCNRC Health74.1×
RVTYRevvity2.5×
MEDPMedpace43.1×
Peer median8.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Celldex Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.